STOCK TITAN
  1. Home
  2. News
  3. CATX

Perspective Therapeutics Inc - CATX STOCK NEWS

Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.

Perspective Therapeutics Inc (CATX) is a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer treatment. This page provides investors and medical professionals with essential updates on the company’s pioneering work in theranostics, which combines therapeutic isotopes with precision imaging diagnostics.

Access real-time announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection offers transparent insights into the company’s progress with 212Pb-based therapies and their applications across oncology specialties.

Key updates cover FDA submissions, peer-reviewed research findings, and manufacturing advancements. Bookmark this page to monitor how CATX’s proprietary targeting peptides and isotope delivery systems are reshaping radiation oncology.

News

Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

Rhea-AI Summary
Perspective Therapeutics, Inc. (CATX) announced the publication of four preclinical studies in support of its discovery pipeline, demonstrating compelling results and continued support for ongoing clinical efforts to advance its novel lead-based targeted alpha-particle therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy

Rhea-AI Summary
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) completes cohort 1 dosing in Phase 1/2a clinical trial of [212Pb]VMT-α-NET for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors (NETs). Rapid recruitment reflects demand for potent alpha-particle therapies. Two active clinical trial sites with plans for 14 more throughout the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
News

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Rhea-AI Summary
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced Q3 financial results and recent business highlights. The company's CEO, Thijs Spoor, highlighted the completion of dosing of the first patient in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors. The company also saw a rebound in the number of patients treated with Cesium-131, marking a return to growth. Notable achievements include significant progress in clinical trials of [212Pb]VMT-α-NET and [212Pb]VMT01, along with positive revenue growth and gross profit increase of 77% compared to the same period last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
earnings
News

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Rhea-AI Summary
Perspective Therapeutics, Inc. (CATX) announced the dosing of the first patient in their Phase 1/2a trial for [212Pb]VMT-α-NET, a targeted alpha-particle therapy for neuroendocrine tumors. The trial aims to evaluate safety and efficacy, with promising data from an investigator-led study in India. With FDA Fast Track Designation, the company plans to advance this product rapidly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

Rhea-AI Summary
Perspective Therapeutics announces two upcoming investigator-initiated trials at NANETS 2023 Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference

Rhea-AI Summary
Perspective Therapeutics presents long-term data on Cesium-131 brachytherapy at ASTRO conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
News

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary
Perspective Therapeutics presents encouraging early clinical results for [212Pb]VMT-α-NET therapy in patients with neuroendocrine tumors and medullary thyroid carcinomas. Initial response seen in 7 out of 9 evaluable patients. Responses observed in both PRRT-naïve and PRRT-refractory disease. No significant adverse events observed. Potential for expansion into other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
clinical trial
-
News

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary
[212Pb]VMT-α-NET shows promise in treating neuroendocrine tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Rhea-AI Summary
Perspective Therapeutics to present at World Molecular Imaging Congress 2023, showcasing positive results for lead-based alpha particle therapies in treating neuroendocrine tumors and image-guided pre-targeted alpha particle therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences
News

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Rhea-AI Summary
Perspective Therapeutics to present new clinical and preclinical data for 212Pb-VMT-α-NET at EANM conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences clinical trial
Stock CATX logo
Perspective Therapeutics Inc

NYSE:CATX

CATX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CATX Stock Data

143.66M
58.95M
20.41%
70.5%
8.74%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SEATTLE